Congoleum Plan Asbestos Trust Fund Claims

Congoleum Plan Trust Facts

Bankruptcy and Trust History

The official Trust states that it was created in 2010 as a result of confirmation of the Congoleum Corporation, et al. Chapter 11 Joint Plan of Reorganization. The audited 2024 financial statements specify that the Trust was established on July 1, 2010 as a Qualified Settlement Fund.

SEC-filed reorganization materials show that the Plan transferred Congoleum asbestos liabilities to the Trust and funded it with multiple assets, including asbestos insurance rights and a majority interest in reorganized Congoleum. Historical Plan materials contemplated approximately $235 million in payments from court-approved asbestos insurance settlements. That amount is historical Plan funding—not the Trust’s current assets.

Who May Qualify for a Congoleum Claim?

The TDP recognizes eight Disease Levels: Mesothelioma, Lung Cancer 1, Lung Cancer 2, Other Cancer, Severe Asbestosis, two Asbestosis/Pleural Disease levels and Other Asbestos Disease.

A claim must satisfy the applicable medical and exposure requirements and establish qualifying Congoleum Exposure. The Trust provides Expedited Review, Individual Review and additional procedures for Extraordinary Claims, Exigent Claims, Secondary Exposure Claims, Foreign Claims and Indirect Claims.

Disease Levels and Claim Values

The First Amended TDP publishes the following base Scheduled, Average and Maximum Values. The Trust’s Notices page also lists a later notice concerning inflation-adjusted TDP values, so these figures are identified here as the base TDP values rather than represented as current inflation-adjusted 2026 values.

Level I is a Cash Discount Payment and, under the TDP, is not subject to the general Payment Percentage. Lung Cancer 2 has no Scheduled Value and is individually evaluated.

Need help now? Call 800.291.0963
Live chat available 24/7, 365 days a year.
Submit Your Case

Current 8.67% Payment Percentage

The Trust’s official October 12, 2023 notice states that, with the consent of the Trust Advisory Committee and Futures Representative, the Payment Percentage was set at 8.67% effective October 12, 2023. The Trust’s audited 2024 annual report subsequently confirms that the Payment Percentage for 2024 was 8.67%.

The 2023 notice separately preserves a 12.5% Released Claims Payment Percentage for claims meeting the notice’s defined Released Claim conditions. That exception must not be confused with the general 8.67% rate.

Mathematical illustration only — not a guaranteed payment. Using the base TDP Mesothelioma Scheduled Value of $120,000 × 8.67% = $10,404. Because the Trust has published inflation-adjusted TDP values and claim-specific rules can apply, this calculation is only an illustration of the percentage—not a current claim quote.

Expedited and Individual Review

Expedited Review is available for seven Disease Levels with Scheduled Values when the claimant satisfies the presumptive medical and exposure criteria. The TDP directs the Trust to offer the applicable Scheduled Value multiplied by the Payment Percentage, subject to payment limitations.

Individual Review permits evaluation of claims that do not meet all presumptive criteria and permits individualized valuation for Disease Levels IV, V, VII and VIII. Lung Cancer 2 is individually evaluated. A value determined through Individual Review can be lower than the Scheduled Value and generally cannot exceed the applicable Maximum Value unless Extraordinary Claim requirements are satisfied.

Medical and Exposure Requirements

The TDP generally requires evidence establishing at least a 10-year latency period between first asbestos exposure and diagnosis.

Mesothelioma Level VIII requires a qualifying mesothelioma diagnosis and Congoleum Exposure before December 31, 1982. Lung Cancer 1 requires primary lung cancer, qualifying underlying bilateral asbestos-related nonmalignant disease, six months of Congoleum Exposure before December 31, 1982, Significant Occupational Exposure and medical documentation supporting asbestos exposure as a contributing factor.

Other Cancer and Severe Asbestosis likewise have disease-specific medical criteria, six-month Congoleum exposure requirements before the cutoff date, Significant Occupational Exposure and supporting medical documentation. The nonmalignant levels have their own radiographic, pulmonary-function and exposure requirements.

2024 Financial and Claims Statistics

The latest annual report currently listed on the Trust’s official Notices page is for fiscal year 2024 and was filed with the U.S. District Court for the District of New Jersey on April 23, 2025.

The audited financial statements separately report $10,872,690 in “claims settled” for 2024. That accrual-basis financial-statement figure is not the same measure as the annual report’s $10,510,464 cash-basis amount paid on 1,110 personal-injury claims, so this page keeps the two concepts separate rather than combining them.

The 304,565 figure is explicitly a count of claims the Trust had not approved since inception. It is not a claims-paid count and is not presented as one.

Confirmed Primary Sources for Trust Facts

No law-firm or lead-generation website was used as factual authority for this page. Primary Trust, court-filed and government-filed materials reviewed include:

• Official Congoleum Plan Trust website.
• Official Trust Resources page.
• Official Trust Notices page.
• Official First Amended Congoleum Plan Trust Distribution Procedures.
• Official October 12, 2023 Payment Percentage notice.
• 2024 Annual Report and audited financial statements filed with the U.S. District Court.
• Official claims-administrator contact information.
• SEC-filed Congoleum reorganization materials.

Get Help Reviewing a Congoleum Asbestos Claim

Call 800.291.0963

Live chat is available 24/7, 365 days a year.

Submit Your Case

Prior exposure to a Congoleum asbestos-containing product does not automatically establish Trust eligibility or compensation. Eligibility depends on medical evidence, exposure evidence, current Trust procedures, applicable filing requirements and individual circumstances. Compensation is not guaranteed.